EMG
XERS icon

ETF Managers Group’s Xeris Biopharma Holdings XERS Stock Holding History

ETF Managers Group’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,428
Closed -$23K – 798
2021
Q1 		$23K Buy
5,428
+1,056
+24% +$5.7K ﹤0.01% 658
2020
Q4 		$22K Buy
+4,372
New +$21.9K ﹤0.01% 614

Other funds holding XERS

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

ETF Managers Group's XERS Position: Q2 2021 in Review

ETF Managers Group sold out of Xeris Biopharma Holdings (XERS) in Q2 2021, closing a stake of 5,428 shares — an estimated $23K sold.

ETF Managers Group first reported a position in XERS in Q4 2020 and held it in 2 quarters. The position peaked at $23K in Q1 2021. 93 funds tracked by Wall St. Rank hold XERS as of Q2 2021.

  • ETF Managers Group reported no remaining Xeris Biopharma Holdings position as of Q2 2021 after selling out during the quarter.
  • ETF Managers Group sold 5,428 Xeris Biopharma Holdings shares in Q2 2021, an estimated $23K.
  • ETF Managers Group first reported a position in Xeris Biopharma Holdings in Q4 2020 and held it in 2 quarters.
  • ETF Managers Group's Xeris Biopharma Holdings position peaked at $23K in Q1 2021.
  • 93 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2021.

Based on ETF Managers Group's 13F filing for Q2 2021, filed 16 Aug 2021.